An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer (ICON6)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00532194 |
Recruitment Status : Unknown
Verified September 2015 by Andrew Embleton, Medical Research Council.
Recruitment status was: Active, not recruiting
First Posted : September 20, 2007
Last Update Posted : September 23, 2015
|
Sponsor:
Medical Research Council
Collaborators:
Cancer Research UK
National Health and Medical Research Council, Australia
Australia New Zealand Gynaecological Oncology Group
NCIC Clinical Trials Group
Grupo Español de Investigación en Cáncer de Ovario
AstraZeneca
Information provided by (Responsible Party):
Andrew Embleton, Medical Research Council
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet
publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending
Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during
QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review
assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific
validity or relevance of the submitted information.
Recruitment Status : | Unknown |
---|---|
Actual Primary Completion Date : | April 2013 |
Estimated Study Completion Date : | December 2016 |
Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
---|---|---|
1 |
March 14, 2016 | April 12, 2016 |
2 |
June 22, 2018 | December 28, 2018 |
Publications of Results:
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Ledermann J, Perren T, Raja F, Embleton A, Rustin GJS, Jayson G, Kaye SB, Swart AM, Vaughan M, Hirte H. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial. Eur J Cancer 2013;49(Suppl. 3):S5 (LBA10).
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):